Core Viewpoint - The article highlights the significant contributions of Li Wenhui in the field of hepatitis B research, particularly his discovery of the hepatitis B virus receptor, which has the potential to lead to more effective treatments for hepatitis B and D [3][12]. Group 1: Research Achievements - Li Wenhui is recognized for his groundbreaking discovery of the sodium taurocholate co-transporting polypeptide (NTCP) as the functional receptor for hepatitis B and D viruses, marking a milestone in the field [12]. - The World Health Organization reported that viral hepatitis is the second leading cause of infectious disease deaths globally, with approximately 1.3 million deaths in 2022, 83% of which were due to hepatitis B [10][11]. - China has around 100 million hepatitis B carriers, with approximately 300,000 deaths annually due to hepatitis-related diseases, highlighting the urgent need for effective treatments [10][11]. Group 2: Company Development - Li Wenhui co-founded the innovative pharmaceutical company Huahui Anjian in 2015, focusing on developing safer and more effective treatments for hepatitis B and D [3][28]. - The company's leading drug, Libeweita, has received acceptance for market application from the National Medical Products Administration and is expected to be approved within the year [29]. - The company emphasizes a culture of openness and high standards, with a principle that if the team would use the drug themselves, then it is worth developing [29]. Group 3: Scientific Philosophy - Li Wenhui believes in the importance of "seeking truth from facts," which fosters an environment conducive to original innovation and rigorous scientific inquiry [23][24]. - The weekly PI Club meetings at the Beijing Institute of Life Sciences encourage open discussions and constructive criticism among scientists, which is crucial for advancing research [25][26]. - Li Wenhui enjoys the exploratory nature of scientific research, likening it to a journey rather than a race, emphasizing the joy found in the process of discovery [19][17].

夏至已过，6月23日北京迎来2025年开年来最炎热的一天。北京生命科学研究所（下称"北生所"）研究员李文辉拉开遮光帘，指着窗外的树说："它们当初那 么细，现在长这么粗了。" 从18年前加入北生所起，李文辉就在这间办公室里工作，研究着一种每年夺去上百万人生命的病毒：乙肝病毒。 李文辉有两个身份，一个是科学家，凭借对乙肝病毒受体的发现，他拿到了大中华区科学界顶尖奖项"未来科学大奖"，也拿到了世界乙肝研究领域最高荣 誉"巴鲁克·布隆伯格奖"。 李文辉的另一个身份，是创新药公司华辉安健的联合创始人。乙肝病毒受体的发现打开了一扇大门，十年前，以此为基础，他和妻子隋建华、北生所另外两 位同事联合创立公司，尝试研发更安全有效的治疗乙肝和丁肝的药物。现在，这家公司进展最靠前、同时也是全球领先的肝病药物已获得国家药监局上市申 请受理，年内有望上市。 低调、务实、真诚，这是李文辉留给许多同行的印象。 前些天，他送给毕业生们一句话：一切幸福和快乐的基础，是你内心的平静和安宁。 李文辉认为，科学不以名头论英雄，被写进历史的成果才是最重要的。"提到牛顿、弗莱明时，人们不会想到他们的头衔，而是万有引力、青霉素"。 现在，提起李文辉，人们 ...